Trial
NCT03552029
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Daiichi Sankyo
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Quizartinib
Why stopped
This study was terminated based on a business decision by the Sponsor.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-20